A
591.87
2.72 (0.46%)
| Previous Close | 589.15 |
| Open | 582.96 |
| Volume | 386,600 |
| Avg. Volume (3M) | 289,661 |
| Market Cap | 36,315,238,400 |
| Price / Earnings (TTM) | 46.31 |
| Price / Earnings (Forward) | 86.96 |
| Price / Sales | 17.37 |
| Price / Book | 6.47 |
| 52 Weeks Range | |
| Earnings Date | 8 May 2025 |
| Profit Margin | 37.05% |
| Operating Margin (TTM) | 13.41% |
| Diluted EPS (TTM) | 12.78 |
| Quarterly Revenue Growth (YOY) | 81.30% |
| Total Debt/Equity (MRQ) | 0.71% |
| Current Ratio (MRQ) | 7.29 |
| Operating Cash Flow (TTM) | -82.75 M |
| Levered Free Cash Flow (TTM) | -143.39 M |
| Return on Assets (TTM) | -0.21% |
| Return on Equity (TTM) | 17.36% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | argenx SE | Bullish | Bullish |
AIStockmoo Score
1.6
| Analyst Consensus | 4.0 |
| Insider Activity | NA |
| Price Volatility | 2.0 |
| Technical Moving Averages | 1.0 |
| Technical Oscillators | -0.5 |
| Average | 1.63 |
|
Argenx is a Dutch company focused on using its antibody engineering technology to treat rare autoimmune diseases. Vyvgart (efgartigimod) was initially approved in the US in December 2021 as a treatment for generalized myasthenia gravis, followed by approvals in Europe and Japan in 2022. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Mid Growth |
| % Held by Institutions | 56.76% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 1,100.00 (Guggenheim, 85.85%) | Buy |
| Median | 704.00 (18.95%) | |
| Low | 680.00 (Baird, 14.89%) | Hold |
| Average | 751.89 (27.04%) | |
| Total | 8 Buy, 1 Hold | |
| Avg. Price @ Call | 630.08 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Guggenheim | 10 Mar 2025 | 1,100.00 (85.85%) | Buy | 571.00 |
| Baird | 04 Mar 2025 | 680.00 (14.89%) | Hold | 621.25 |
| Citizens Capital Markets | 28 Feb 2025 | 701.00 (18.44%) | Buy | 624.67 |
| HC Wainwright & Co. | 28 Feb 2025 | 720.00 (21.65%) | Buy | 624.67 |
| 14 Jan 2025 | 717.00 (21.14%) | Buy | 665.60 | |
| Oppenheimer | 28 Feb 2025 | 704.00 (18.95%) | Buy | 624.67 |
| Wells Fargo | 28 Feb 2025 | 741.00 (25.20%) | Buy | 624.67 |
| JMP Securities | 14 Jan 2025 | 696.00 (17.59%) | Buy | 665.60 |
| Truist Securities | 14 Jan 2025 | 700.00 (18.27%) | Buy | 665.60 |
| Piper Sandler | 07 Jan 2025 | 725.00 (22.49%) | Buy | 648.62 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 07 Mar 2025 | Announcement | argenx Highlights FcRn Leadership with Long-term Data and Transformational Patient Outcomes at the American Academy of Neurology 2025 Annual Meeting |
| 27 Feb 2025 | Announcement | argenx Reports Full Year 2024 Financial Results and Provides Fourth Quarter Business Update |
| 25 Feb 2025 | Announcement | argenx to Present at TD Cowen 45th Annual Healthcare Conference |
| 20 Feb 2025 | Announcement | argenx to Report Full Year 2024 Financial Results and Fourth Quarter Business Update on February 27, 2025 |
| 13 Jan 2025 | Announcement | argenx Highlights 2025 Strategic Priorities |
| 06 Jan 2025 | Announcement | argenx to Present at 43rd Annual J.P. Morgan Healthcare Conference |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |